Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Lacerta Therapeutics on the deal. Lacerta Therapeutics announced its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
You must be a Standard 1 Year member to access this content.
